Valbenazine and Deutetrabenazine for Tardive Dyskinesia

Conclusion Valbenazine and deutetrabenazine offer a unique mechanism of action for the treatment of TD and are the first treatments to be FDA-approved for this condition. The high level of available evidence warrants clinical consideration for patients who are not candidates for a dose reduction or change in antipsychotic therapy with moderate-to-severe TD. It is important to note that the data on quality of life are scarce and that AIMS scores do not correlate with functional or social impairment. Additional studies and data are needed regarding the effects of valbenazine and deutetrabenazine on quality of life and their long-term benefits and safety. References American Psychiatric Association. Medication Induced Movement Disorders and Other Adverse Effects of Medication. In: Diagnostic and Statistical Manual of Mental Disorders. 5th ed.. Washington DC: American Psychiatric Publishing; 2013: 709–714. Correll CU, Schenk EM. Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry. 2008;21(2):151–156. Margolese HC, Chouinard G, Kolivakis TT, et al. Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 1: pathophysiology and mechanisms of induction. Can J Psychiatry. 2005;50(9):541–547. Lister J, Nobrega JN, Fletcher PJ, et al. Oxidative stress and the antipsychotic-induced vacuous chewing movement model of tardive dyskinesia: evidence for antioxidant-based prevention strategies. Psychopharmacology (Berl). 2014;231(11):2237–2249. Bhidayasir...
Source: Innovations in Clinical Neuroscience - Category: Neuroscience Authors: Tags: Current Issue Review deutetrabenazine tardive dyskinesia Valbenazine Source Type: research